Find insight on Novartis, Masimo, Fisher & Paykel and more in the latest Market Talks covering Health Care.

Medical device maker Fisher & Paykel Healthcare faces a significant impact from potential tariffs in the US, say research ...

Goldman Sachs analyst Davin Thillainathan initiated coverage of Fisher & Paykel Healthcare with a Buy rating and A$42.70 price target The firm sees an acceleration of revenue in the company’s ...

Initial US respiratory data indicates Fisher & Paykel Healthcare (FPH) is likely to reach the top end of its guidance of ...

The top 10 Australian share funds of 2024 have been revealed, with the reigning champion retaining its crown for a second straight year, according to a Mercer investment survey.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...

Goldman Sachs began coverage on Fisher & Paykel Healthcare (FPH:AU) (OTC: FSPKF), issuing a Buy rating and setting a price target of NZD42.70. The firm's positive stance on the healthcare company is ...

Donald Trump officially got the keys back to the White House earlier this week - and his return to power could have an impact ...

The New Zealand sharemarket ended a strong week with a gain of more than 1.8%, erasing the year’s earlier losses, and powered ...